Cohance Lifesciences Ltd., a leading integrated Contract Development and Manufacturing Organization (CDMO), has announced the appointment of Yann D’Herve as the new Chief Executive Officer of its CDMO division, effective August 1, 2025.
D’Herve brings over two decades of global leadership experience across pharmaceuticals, healthcare, and specialty chemicals. Known for his strategic vision and operational expertise, he has held multiple senior roles at Evonik, including Senior Vice President and General Manager of its Healthcare division. In that role, he oversaw 2,600 employees across nine manufacturing facilities and managed full P&L responsibilities, including CDMO operations.
Before that, D’Herve served as Vice President of Sales and Services at Evonik and held several leadership positions across manufacturing and commercial functions. He began his career on the shop floor, gaining valuable hands-on experience in production and operations.
Cohance Lifesciences’ CDMO platform offers end-to-end capabilities in small molecule APIs, Antibody Drug Conjugates (ADCs), and Nucleic Acid Chemistry, supporting global pharmaceutical innovators.
D’Herve holds an MBA from Université de Picardie Jules Verne, Amiens, and a master’s degree in chemistry from CPE Lyon, France. His appointment marks a strategic move by Cohance to strengthen its leadership and expand its innovation-led services for the global pharma industry.
